Bharat Biotech advises certain groups against taking its COVID-19 vaccine

pharmafile | January 19, 2021 | News story | Manufacturing and Production Bharat Biotech, COVID-19 

India’s vaccine developer Bharat Biotech has advised a number of groups to avoid taking its homegrown COVID-19 vaccine, Covaxin.

According to a fact sheet published by the company, pregnant and breastfeeding women, those with allergies, and people suffering from any kind of medical disorder should not be given the locally-produced jab.

Covaxin has been at the centre of controversy after it was approved for use in India before Phase III trials into its clinical efficacy have been completed. Bharat has insisted their vaccine is safe and effective.

The company has advised people to avoid having the Covaxin jab if they:

  • Have any history of allergies
  • Have a high fever
  • Have a bleeding disorder or are a blood thinner
  • Are immune compromised or are on medication that affects your immune system
  • Are pregnant
  • Are breast feeding
  • Have received another COVID-19 vaccine
  • Have any other serious health related issues, as determined by the vaccinator or officer supervising vaccination

The firm said people should disclose any medical conditions they have, any medicines they are taking, and any history of allergies before being vaccinated.

Bharat’s recommendations come as two people have died in India after receiving COVID-19 vaccines. On Sunday, a hospital worker died shortly after being administered Covishield, India’s other COVID-19 vaccine. The death of a second man just days after being vaccinated was reported on Monday, although it is unclear which jab he received. The Indian government has said neither of the country’s coronavirus vaccines are responsible for the deaths.

Darcy Jimenez

Related Content

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …

The NIH’s RECOVER initiative could lead to the first official treatment for long COVID-19

As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials …


Moderna files for FDA authorisation for updated COVID-19 vaccine

Biotechnology company Moderna has announced that it has completed submission of a regulatory application to …

Latest content